

## **Study Specific Spirometry Testing**


Study AC-060A202 CONTROL Dorothea Scholl

Strictly confidential





## AC-060A202 study will use spirometry testing to determine the primary endpoint (FEV1)



Denison's Spironeter from Esercise and Food for Pulmonary Invalids: Charles Denison AM MD. Denver: The Chain & Hardy Co; 1995. Courtesy Health Sciences Libraries, University of Washington



## Pulmonary Function Testing in Clinical Practice vs. Clinical Trials

- In clinical practice accuracy important but not critical in making a diagnosis
  - combination with history and symptoms
  - looking at trends and general changes
- · Clinical trials looks at specific changes and specific changes over time.
  - Accuracy is critical.
  - 50 -100 mL may make a difference in the outcome for a drug
  - 50 -100 mL may be the intra-subject variability at one Visit



#### **Parameters**

- FEV1 (mL)
- FVC (L)
- FEV1/FVC (%)
- PEF (L/sec and L/min (daily peak flow meter))
- FEF25-75% (L/sec)
- Predicted
- % ofP
- Meas (actual)
- % change
- Comp (best test values that will be reported into the database, can come from different efforts)
- B-meas (test from which the FEV1 will be reported)

AC-060A202: CONTROL – Spirometry Testing

Investigators Meeting, Barcelona - 20 & 21 January 2010



#### **Predicted Normal Values**

• Quanjer et al, 1993:

Gender	Equation
Male	4.30 H - 0.029 A - 2.49
Female	3.95 H – 0.025 A - 2.60

H: Standing height (m); A: Age (yr); between 18 and 25 years, substitute 25 years in the equations

 All ethnic groups other than white/caucasian will be race adjusted by a factor conversion factor of 0.9 prior to calculation of FEV1 %oP.

FEV1 predicted normal (patient of ethnic group other than white/caucasian) = FEV1 predicted normal x 0.9



#### **Spirometry Testing in the Study**



- Pre/Post Spirometry testing must be done at all Visits.
- Reversibility criteria must be met at visit 1 OR 2 (hence the pre/post test is referred to as "Reversibility Testing" at these visits)




#### **Avoid the Following Prior to Site Visit:**

- Caffeine-containing drinks (1 hr)
- Alcoholic beverages (4 hrs)
- Strenuous exercise (30 minutes)
- Large meals (2 hrs)
- Cold air



DO NOT TAKE SALBUTAMOL/ALBUTEROL FOR 6 HOURS PRIOR TO TEST.

If so, please reschedule



AC-060A202: CONTROL - Spirometry Testing

Investigators Meeting, Barcelona - 20 & 21 January 2010



#### **Performing the Spirometry Test**

- Enthusiastic coaching
- Encouragement throughout the test
- Rest between efforts
- Bronchodilator with spacer (wait 15-45 minutes to do post test)
- Repeatable testing between efforts (according to ATS)



#### **Errors**

- Poor effort
- Inconsistent effort
- Coughing
- False start or hesitant start
- Exhalation too shorte



Patients that cannot perform acceptable and repeatable tests according to ATS/ERS guidelines should not be enrolled or randomized into the study



#### **Assessing the Data**



- Minimum 3 efforts
- Maximum 8 efforts
- Acceptable
- Repeatable
- "best"



#### **Assessing the Data**

- After each effort should be assessed if the effort is acceptable.
- Discard not acceptable data
  - Still counts as an effort but will not be used in the choice of "best" or "reported" value
- Continue to do another effort until a maximum of 8 efforts or 2 repeatable.
- Repeatable Criteria
  - Compare the two tests with the largest FEV1 and FVC
- Report the "best or largest"
  - largest values for the FEV1 and FVC can come different efforts



#### **Acceptable Criteria**

- No cough
- Back extrapolation <%5 of FVC or 150mL(whichever is greater)</li>
- Minimum 6 seconds exhalation
- Plateau at end of exhalation




#### **Repeatability Criteria**

- Good effort
- Two largest FEV1 within 150 mL
- Two largest FVC within 150 mL
- Two largest PEF within 0.67 L/sec




#### **Efforts Must Be Maximal**









AC-060A202: CONTROL - Spirometry Testing

Investigators Meeting, Barcelona - 20 & 21 January 2010



#### "Best" Test / Reported Value for Endpoints

- Largest FVC
- Largest FEV1
- Largest PEFR
- FEF 25-75% comes from the "best" (trial with largest sum of FEV1 plus FVC)



#### **Assessing the Tests**

- Investigator to confirm the spirometry results
  - Please ensure that the effort with the "Best" FEV1 is acceptable
    - No coughing, maximal effort, consistent effort, no false start
    - If not acceptable, discard that value and choose a new "Best"





Last Test; 24/SEP/2010 1

#### **Reports**

#### Pre

 Subject #: 10001
 Initials:
 Race: Black

 Bender: M
 Age: 20
 Date of Birth: 01/JAN/19

 Position Sitting
 Height: 160.0
 Weight: 190.0

 Visit: Visit 3-Week 1 (3)
 Interval: Pre FVC (1)
 Stage: V3 Pre FVC (1)

 Randomization #:
 Eurollment Code:
 Tech: rbucha\_sa

Predicteds: ECCS-Actalian

First Test: 24/SEP/2010 19:44:51 Best Test: 24/SEP/2010 19:44:51

Report Comments: Subject's Reference Value: 2.58 Stability: PEF % change=18.9 FEV1 % change=18.9

Baseline Visit Results:


#### Only on Post

nSpire Site ID: 1 PI: No Primary Investigator

Function	Baseline	Current Best	% Change	ml Difference		
FVC (L)	2.95	2.44	-17.29	-510.00		
FEVI(L)	2.38	2.27	-4.62	-110.00		
FEVI/FVC (%)	80.68	93.03	15.31	n/a		
PEF(L/S)	5.60	5.69	161	90.00		
FEF25-75% (L/S)	2.12	2.98	40.57	n/a		

Actelion Pharmaceuticals Ltd.
AC-0604202 (CONTROL)

Attempts for this Stage: 2. Ranking order: 1,2 Graphs in Rank Order



Authorized Signature: Date:

Repeatability Check NOT Reached.(FVC & FEV1)

Function	Pred	B-Meas	%Prd	Meas						
FVC (L)	3.8	3.64	95.8%	3.21						
FEV1(L)	3.3	3.03	91.8%	2.64						
FEV1/FVC (%)	0.74	0.83	112.2%	0.82						
PEF(L/S)	8.9	6.87	77.2%	6.28						
FEF25-75% (L/\$)	4.73	3.03	64.1%	2.70						
VEXTL		0.06		0.05						
VEXT (%)		1.55		1.47						
FLAGS		6SEC BST		6SEC						
EXP TIME		3.13		3.57						

18

AC-060A202: CONTROL - Spirometry Testing

Investigators Meeting, Barcelona - 20 & 21 January 2010



#### **Inclusion Criteria**

- At Visit 1 AND Visit 2
  - FEV1 ≤ 85%
  - No waivers granted if not reached
  - If 85.4% is acceptable as it would be rounded down
  - 85.5% would not be acceptable
- At Visit 1 OR Visit 2
  - Post FEV1 Reversibility of 12% AND 200 mL
  - 11.5% acceptable 11.4% not
  - 199mL not acceptable



#### Peak Exploratory Flow Spirometer vs Daily PiKo



L/min 306 Blast out 2-3 sec.



L/sec

5.1

Blast out 6 sec.



#### **Reversibility Testing**

- Wait 15-45 minutes to perform Post testing
- Must be used for all pre/post (reversibility testing at site
- · Patient should use at home
- Patient to bring to each visit






### **Spirometry Examples**




#### **Poor Effort**



Quanjer et. al. http://spirxpert.com/characteristic.htm




#### **Premature Termination**



Quanjer et. al. http://spirxpert.com/characteristic.htm




#### **False Start**



Quanjer et. al. http://spirxpert.com/characteristic.htm




#### **Variable Effort**



Quanjer et. al. http://spirxpert.com/characteristic.htm




#### Cough





Quanjer et. al. http://spirxpert.com/characteristic.htm





#### Within maneuver acceptability criteria


















28












AC-060A202: CONTROL - Spirometry Testing

29


Investigators Meeting, Barcelona - 20 & 21 January 2010







#### Submaximal Effort



Reference: Mottram. Mayo Clinic. http://www.dap.org/CmsFiles/File/Conferences/PFQC%20May%201%20and%202/Presentations/C-Mottram-Spirometry%20QA%20Models.pdf



#### **Summary**

- Only patients that can do repeatable/acceptable test to be enrolled
- Postpone visit if patient took salbutamol/albuterol within 6 hours prior to schedule spirometry at the visit
- Please use robust coaching techniques
- At Visit 1 do peak flow diary first to set the baseline values
- Salbutamol/albuterol to be given via spacer at each Visit
- Must do post testing within 15-45 minute window
- Encourage spacer use at home
- Examine efforts and discard those that are not acceptable
- Ensure that the "best" test values do not come from unacceptable efforts
- Spirometry alerts (i.e. drop in PEF) are warnings but do not necessitate withdrawal from the study. Please use your clinical judgment whether the patient can continue or not.



#### Standards/Guidelines

- ATS Guidelines
   <a href="http://thoracic.org/statements/">http://thoracic.org/statements/</a>
- ERS
   http://www.ersnet.org/4/1/4\_1.asp
- Global Initiative for Asthma (Gina) <a href="http://www.ginasthma.com/">http://www.ginasthma.com/</a>



## The achievements of an organization are the results of a combined effort of each individual





34

AC-060A202: CONTROL - Spirometry Testing

Investigators Meeting, Barcelona - 20 & 21 January 2010



# Thank you for your efforts and all the best!!